Eton Pharmaceuticals (NASDAQ:ETON) Stock Rating Upgraded by Zacks Research

Eton Pharmaceuticals (NASDAQ:ETON) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other equities analysts have also commented on ETON. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright boosted their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a report on Friday, August 14th. Canaccord Genuity Group increased their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Finally, Craig Hallum raised their target price on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Eton Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $67.50.

Eton Pharmaceuticals Stock Performance

ETON opened at $63.05 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. The business has a fifty day simple moving average of $43.42 and a 200 day simple moving average of $31.03. Eton Pharmaceuticals has a 1 year low of $14.27 and a 1 year high of $66.37. The company has a market capitalization of $1.80 billion, a PE ratio of 165.92 and a beta of 0.86.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.24. The firm had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. Research analysts expect that Eton Pharmaceuticals will post 0.67 EPS for the current year.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, insider David Krempa sold 25,000 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the transaction, the insider owned 37,025 shares in the company, valued at approximately $2,409,216.75. This trade represents a 40.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 16.49% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $68,629,000. Nantahala Capital Management LLC acquired a new position in Eton Pharmaceuticals during the second quarter valued at approximately $42,569,426,000. Pillsbury Lake Capital LLC acquired a new position in Eton Pharmaceuticals during the second quarter valued at approximately $14,015,083,000. Soleus Capital Management L.P. bought a new stake in Eton Pharmaceuticals during the second quarter worth $4,061,000. Finally, Millennium Management LLC boosted its holdings in shares of Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares in the last quarter. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.